日前美國(guó)耶魯大學(xué)研究人員表示,，他們發(fā)現(xiàn)了一種可以預(yù)測(cè)卵巢癌患病風(fēng)險(xiǎn)的遺傳標(biāo)記。相關(guān)研究20日發(fā)表在美國(guó)《癌癥研究》雜志網(wǎng)絡(luò)版上,。
研究人員發(fā)現(xiàn),，25%的卵巢癌患者體內(nèi)都存在KRAS基因的一個(gè)變種，而普通人只有6%擁有這一變種,；這一變種還在61%有乳腺癌及卵巢癌家族病史的卵巢癌患者體內(nèi)出現(xiàn),。此外，與擁有其他致病基因變種的女性通常在年輕時(shí)患卵巢癌不同,，擁有KRAS基因變種的女性更傾向于在絕經(jīng)后患卵巢癌,。
負(fù)責(zé)這項(xiàng)研究的耶魯大學(xué)癌癥中心治療放射學(xué)副教授喬安妮·魏德哈斯表示,，對(duì)擁有嚴(yán)重卵巢癌家族病史的女性而言，KRAS基因的變種可成為預(yù)測(cè)她們患卵巢癌風(fēng)險(xiǎn)的遺傳標(biāo)記之一,。
卵巢癌是最致命的婦科癌癥之一,，早期很難診斷，患者的5年生存率在40%以下,。(生物谷Bioon.com)
生物谷推薦原文出處：
Cancer Reserch doi: 10.1158/0008-5472.CAN-10-0689
A KRAS-Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer Risk
Elena Ratner1, Lingeng Lu2, Marta Boeke3, Rachel Barnett4, Sunitha Nallur3, Lena J. Chin6, Cory Pelletier3, Rachel Blitzblau3, Renata Tassi7, Trupti Paranjape3, Pei Hui5, Andrew K. Godwin8, Herbert Yu2, Harvey Risch2, Thomas Rutherford1, Peter Schwartz1, Alessandro Santin1, Ellen Matloff4, Daniel Zelterman2, Frank J. Slack6, and Joanne B. Weidhaas3
Ovarian cancer (OC) is the single most deadly form of women's cancer, typically presenting as an advanced disease at diagnosis in part due to a lack of known risk factors or genetic markers of risk. The KRAS oncogene and altered levels of the microRNA (miRNA) let-7 are associated with an increased risk of developing solid tumors. In this study, we investigated a hypothesized association between an increased risk of OC and a variant allele of KRAS at rs61764370, referred to as the KRAS-variant, which disrupts a let-7 miRNA binding site in this oncogene. Specimens obtained were tested for the presence of the KRAS-variant from nonselected OC patients in three independent cohorts, two independent ovarian case-control studies, and OC patients with hereditary breast and ovarian cancer syndrome (HBOC) as well as their family members. Our results indicate that the KRAS-variant is associated with more than 25% of nonselected OC cases. Further, we found that it is a marker for a significant increased risk of developing OC, as confirmed by two independent case-control analyses. Lastly, we determined that the KRAS-variant was present in 61% of HBOC patients without BRCA1 or BRCA2 mutations, previously considered uninformative, as well as in their family members with cancer. Our findings strongly support the hypothesis that the KRAS-variant is a genetic marker for increased risk of developing OC, and they suggest that the KRAS-variant may be a new genetic marker of cancer risk for HBOC families without other known genetic abnormalities.
